Kymab raises $100M in series C round

Antibody platform company Kymab Group Ltd. (Cambridge, U.K.) raised a $100 million series C round led by new investors ORI Healthcare Fund and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399). Shenzhen Hepalink invested $36.5 million.

Also participating were existing shareholders Wellcome Trust, the Bill & Melinda Gates Foundation, Malin Corp. plc (ISE:MLC), CF Woodford Equity Income Fund and Woodford Patient Capital plc...